BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, Tejada S, Abete I, Zulet MA, Tur JA, Martínez JA, Sureda A. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2020;9:E759. [PMID: 32824349 DOI: 10.3390/antiox9080759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sohrabi M, Gholami A, Amir Kalali B, Khoonsari M, Sahraei R, Nasiri Toosi M, Zamani F, Keyvani H. Are Serum Levels of Nuclear Factor Kappa B and Forkhead Box Protein P3 in Patients with Non-Alcoholic Fatty Liver Disease Related to Severity of Fibrosis? Middle East J Dig Dis 2021;13:356-62. [DOI: 10.34172/mejdd.2021.247] [Reference Citation Analysis]
2 Senesi P, Luzi L, Terruzzi I. Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions. Int J Mol Sci 2020;21:E8372. [PMID: 33171610 DOI: 10.3390/ijms21218372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Monserrat-Mesquida M, Quetglas-Llabrés M, Bouzas C, Capó X, Mateos D, Ugarriza L, Tur JA, Sureda A. Peripheral Blood Mononuclear Cells Oxidative Stress and Plasma Inflammatory Biomarkers in Adults with Normal Weight, Overweight and Obesity. Antioxidants (Basel) 2021;10:813. [PMID: 34065281 DOI: 10.3390/antiox10050813] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Carneros D, López-Lluch G, Bustos M. Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E3472. [PMID: 33198247 DOI: 10.3390/nu12113472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Opazo-ríos L, Soto-catalán M, Lázaro I, Sala-vila A, Jiménez-castilla L, Orejudo M, Moreno JA, Egido J, Mas-fontao S. Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice. IJMS 2022;23:3965. [DOI: 10.3390/ijms23073965] [Reference Citation Analysis]
6 Martinez-Urbistondo D, Suarez Del Villar R, Argemí J, Daimiel L, Ramos-López O, San-Cristobal R, Villares P, Martinez JA. Antioxidant Lifestyle, Co-Morbidities and Quality of Life Empowerment Concerning Liver Fibrosis. Antioxidants (Basel) 2020;9:E1125. [PMID: 33202851 DOI: 10.3390/antiox9111125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dong B, Chen Y, Lyu G, Chen Y, Qin R. Quantitative Assessment of Portal Hypertension by Two-Dimensional Shear Wave Elastography in Rat Models of Nonalcoholic Fatty Liver Disease: Comparison With Four Composite Scores. Front Med 2022;9:844558. [DOI: 10.3389/fmed.2022.844558] [Reference Citation Analysis]
8 Yu Y, Tian T, Tan S, Wu P, Guo Y, Li M, Huang M. MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. Bioengineered 2022;13:2927-42. [PMID: 35038955 DOI: 10.1080/21655979.2021.2017698] [Reference Citation Analysis]
9 Karami S, Poustchi H, Sarmadi N, Radmard AR, Ali Yari F, Pakdel A, Shabani P. Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease. Diabetol Metab Syndr 2021;13:121. [PMID: 34702329 DOI: 10.1186/s13098-021-00741-5] [Reference Citation Analysis]